LEO Pharma Open Innovation

Eczematous inflammation

Primary human keratinocytes are stimulated with a cytokine cocktail containing IL-4, IL-13, IL-22 & IFN-gamma, to induce an eczema-relevant response, detected as an increase in CCL2 release. Your compound is tested for its ability to inhibit the inflammatory response, measured as an inhibition of CCL2 release. Cell viability is also assessed, as a measure of general compound cytotoxicity.

How the biological assay works